Skip to main content
SpringerLink
Log in

Gemcitabine: Safety profile and efficacy in non-small cell lung cancer unaffected by age

  • Original Article
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Gemcitabine, a novel anticancer agent, was demonstrated to be well tolerated in both elderly and younger patients. Safety data were collected from 18 completed clinical studies (790 patients) in a variety of solid tumor types. All studies used a starting dose of 800–1250 mg/m2 administered once a week for 3 weeks followed by a week of rest. Patients were initially divided using a cut-off age of 65 years, and subsequently using a cut-off age of 70 years. Gemcitabine was well tolerated by patients of all ages, with few clinically meaningful differences between the age groups. Gemcitabine was also found to be as efficacious in older patients as in younger ones. Efficacy data was collected from four studies (329 evaluable patients) in non-small cell lung cancer with consistent response rates of 20%. When patients were divided into two groups, those aged below 70 years and those 70 years and above, the response rates were 19.0% (95% C.I., 14.6–23.4) and 25.0% (95% C.I., 10.0–40.0) respectively. In conclusion, elderly patients should benefit from gemcitabine treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Phister J.E., Jue S.E., Cusack B.J.: Problems in the use of anticancer drugs in the elderly. Drugs 37: 551–565, 1989.

    Article  CAS  PubMed  Google Scholar 

  2. Walsh S.J., Begg C.B., Carbone P.P.: Cancer chemotherapy in the elderly. Semin. Oncol. 16: 66–75, 1989.

    CAS  PubMed  Google Scholar 

  3. Grindey G.G., Boder G.B., Hertel L.H., Kroin J.S., Poore G.A., Rinzel S.M., Todd G.C.: Antitumor activity of 2′,2′-difluorodeoxycitidine (LY188011). Proc. Am. Assoc. Cancer Res. 27, 1986, p. 296 (A 1775).

    Google Scholar 

  4. Chubb S., Heinemann V., Novotny L., Hertel L., Nowak B., Mineishi S., Grindey G.B., Plunkett W.: Metabolism and action of 2′,2′-difluorodeoxycytidine (dFdC) in human leukemia cell. Proc. Am. Assoc. Cancer Res. 28, 1987, p. 324 (A 1282).

    Google Scholar 

  5. Bhalla K., MacLaughlin W., Cole J., Arlin Z., Birkhofer M., Graham G.: Continuously administered 2′,2′-difluorodeoxycytidine (dFdC) and deoxycytidine (dCyd): A potentially selective cytotoxic regimen toward human leukemic myeloid progenitors in culture. Proc. Am. Assoc. Cancer Res. 28, 1988, p. 348 (A 1385).

    Google Scholar 

  6. Fujita F., Fijita M., Inaba H., Taguchi T.: Antitumor activity of LY188011, a new deoxycytidine analog, against human cancers xenografted into nude mice. Jpn. J. Cancer Chemother. 21: 517–523, 1994.

    CAS  Google Scholar 

  7. Tanayanagi C., Takauji R., Ueda T.: Action mechanism of difluorodeoxycitidine (dFdC), a new ara-C derivative. Acta Hematol. Jpn. 53: 76, 1990 (A 132).

    Google Scholar 

  8. Bouffard D.Y., Momparler L.F., Momparler R.L.: Comparison of antineoplastic activity of cytosine arabinoside and 2′,2′-difluorodeoxycytidine on human myelod, T-cell and B-cell leukemic cells. Eur. J. Pharmacol. 183, 161, 1990 (A 32).

    Article  Google Scholar 

  9. Plunkett W., Chubb S., Nowak B., Hertel L., Grindey G.B.: Increased cytotoxicity and therapeutic activity of 2′,2′-difluorodeoxycytidine over cytosine arabinoside (ara-C) in L1210 leukemia. Proc. Am. Assoc. Cancer Res. 29, 1988, p. 352

    Google Scholar 

  10. Anderson H., Lund B., Bach F., Thatcher N., Walling J., Hansen H.H.: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study. J. Clin. Oncol. 12: 1821–1826, 1994.

    CAS  PubMed  Google Scholar 

  11. Gatzemeier U., Shepherd F.A., Le Chevalier T., Weynants P., Cottier B., Groen H.J., Rosso R., Mattson K., Cortes-Funes H., Tonato M., Burkes R.L., Gottfried M., Voi M.: Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter extended phase II study. Eur. J. Cancer 32: 243–248, 1996.

    Article  Google Scholar 

  12. Kaye S.B.: Gemcitabine current status of phase I and II trials. J. Clin. Oncol. 12: 1527–1531, 1994.

    CAS  PubMed  Google Scholar 

  13. Abratt R.P., Werner R.B., Falkson G., Goedhals L., Hacking D., Rugg T.: Efficacy and safety of gemcitabine in non-small cell lung cancer: A phase II Study. J. Clin. Oncol. 12: 1535–1540, 1994.

    CAS  PubMed  Google Scholar 

  14. Walling J.: Chemotherapy of advanced non-small cell lung cancer. Respir. Med. 88: 649–657, 1994.

    Article  CAS  PubMed  Google Scholar 

  15. Carmichael J., Fink U., Russell R.C.G., Spittle M.F., Harris A.L., Spiessi G., Blatter J.: Phase II Study of gemcitabine in patients with advanced pancreas cancer. Br. J. Cancer 73: 101–105, 1996.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Casper E.S., Green M.R., Kelsen D.P., Heelan R.T., Brown T.D., Flombaum C.D., Trochanowski B., Tarassoff P.G.: Phase II trial of gemcitabine (2′,2′difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs 12: 29–34, 1994.

    Article  CAS  PubMed  Google Scholar 

  17. Lund B., Hansen O.P., Theilade K., Hansen M., Neijt J.P.: Phase II study of gemcitabine (2′,2′-difluorodeoxycitidine) in previously treated ovarian cancer. J. Natl. Cancer Inst. 86: 1530–1533, 1994.

    Article  CAS  PubMed  Google Scholar 

  18. Carmichael J., Possinger K., Phillip P., Beykirch M., Kerr H., Walling J., Harris A.L.: Advanced breast cancer: A Phase II trial with gemcitabine. J. Clin. Oncol. 13: 2731–2736, 1995.

    CAS  PubMed  Google Scholar 

  19. Cormier Y., Eisenhauer E., Muldal A., Gregg R., Ayoub J., Gross G., Stewart D., Tarasoff P., Wong D.: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Treatment Group. Ann. Oncol. 5: 283–285, 1994.

    CAS  PubMed  Google Scholar 

  20. De Mulder P.H.M., Weissbach L., Jakse G., Osieka R., Blatter J.: Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother. Pharmacol. 37: 491–495, 1996.

    Article  PubMed  Google Scholar 

  21. Merterns W.C., Eisenhauer E.A., Moore M., et al.: Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials group. Ann. Oncol. 4: 331–332, 1994.

    Google Scholar 

  22. Abbruzzese J.L., Pazdur R., Ajani J., Daugherty K., Tarassoff P., Levin B.: A phase II trial of gemcitabine in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 10: 456, 1991.

    Google Scholar 

  23. Christman K., Kelsen D., Saltz L., Tarassoff P.G.: Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 73: 5–7, 1994.

    Article  CAS  PubMed  Google Scholar 

  24. Poplin P., Thompson B., Whitacre M.: Small cell carcinoma of the lung: influence of age on treatment outcome. Cancer Treat. Rep. 71: 290–296, 1987.

    Google Scholar 

  25. Rinaldi M., De Marinis F., Ardizzoni A.: Correlation between age and prognosis in patients with advanced non small cell cancer (NSCLC) treated with cisplatin (CDDP) containing chemotherapy: a retrospective multicenter study. Ann. Oncol. 5 (Suppl. 8): 58, 1994.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lilly Research Centre Ltd., Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK

    C. Martin

  2. Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

    A. Ardizzoni & R. Rosso

Authors
  1. C. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Ardizzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Rosso
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, C., Ardizzoni, A. & Rosso, R. Gemcitabine: Safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging Clin Exp Res 9, 297–303 (1997). https://doi.org/10.1007/BF03341832

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03341832

Key words

Search

Navigation